Developer docs
API playgroundTry for free, no card

Search company profiles

Logenex Pharm Gmbh

Full company profile

uuid02l8j3q

Namestring
Logenex Pharm Gmbh
Legal namestring
LOGENEX Pharm GmbH
Company typeenum
Private
Founded yearint
2009
Descriptiontext

LOGENEX Pharm GmbH is a privately held German pharmaceutical company headquartered at Martinistrasse 13, Hamburg, operating under the legal form of a Gesellschaft mit beschränkter Haftung (GmbH). The company specializes in the development and distribution of high-quality generic and niche pharmaceuticals targeted at specific therapeutic areas, with a current product portfolio of five core SKUs: Anatrofer® 1000 mg (sodium hydrogen carbonate gastro-resistant tablets for metabolic acidosis in chronic kidney disease), Bortezomib 3.5 mg injection, Pemetrexed 500 mg infusion, Testosteron 1000 mg/4 mg injection, and Zoledronsäure 4 mg/5 ml infusion concentrate. All products are manufactured, tested, and released in certified production facilities within the European Union in strict accordance with Good Manufacturing Practice (GMP) guidelines; the company itself holds a wholesale distribution authorization under § 52a (1) of the German Medicines Act (AMG), issued by the Hamburg authority responsible for medicinal products and consumer protection.

The company operates an asset-light, B2B go-to-market model. Products are registered and marketed through a network of distribution partners across Europe, North Africa, the Middle East, Southeast Asia, and Latin America. Three partners anchor the distribution architecture: CNX Therapeutics handles international specialty and hospital channels across 35+ countries, CareCept Medical serves as the sales and distribution partner in Germany with a focus on oncology, and PharmIdea SIA functions as a strategic co-development partner for sterile formulation manufacturing in gynecology and oncology. End customers are healthcare professionals, hospital systems, and patients requiring treatment in nephrology (specifically CKD-related metabolic acidosis) and oncology. Revenue is generated through product sales via this partner channel structure; the company lists "one-time license" revenue streams and pricing is not publicly disclosed. The organization is led by General Manager (Geschäftsführer) Frank Materne, with no disclosed external ownership, venture backing, or public listing.

The company's competitive positioning rests on EU GMP manufacturing provenance, a niche therapeutic focus in CKD metabolic acidosis and oncology, and supply reliability for healthcare system partners. The headquarters is registered with the District Court of Hamburg under HRB 110224.

Short descriptiontext

LOGENEX Pharm GmbH is an independent German pharmaceutical company based in Hamburg that develops and distributes EU-manufactured generic and niche pharmaceuticals, primarily for nephrology (CKD metabolic acidosis) and oncology, via a partner distribution network across Europe, North Africa, the Middle East, Southeast Asia, and Latin America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHamburg, Germany
HQ citystring
Hamburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generic pharmaceuticals, pharmaceutical wholesale distribution, nephrology therapeutics, oncology generics, hospital specialty medicines
Industry3 codes
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Pharmaceutical Preparations2834
Product category
Generic Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Generic Pharmaceuticals
TypeOne Time License
Description

Development and distribution of high-quality generic pharmaceuticals and niche products for specific therapeutic areas including chronic kidney disease and oncology.

logenex-pharm.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

LOGENEX Pharm GmbH is an independent German pharmaceutical company that develops and distributes high-quality generic and niche pharmaceutical products for specific therapeutic areas, primarily chronic kidney disease (metabolic acidosis) and oncology. Products are sourced exclusively from qualified manufacturers within the European Union and manufactured, tested, and released under strict Good Manufacturing Practice (GMP) guidelines. Marketing and distribution are executed through a network of wholesale and channel partners across Europe, North Africa, the Middle East, Southeast Asia, and Latin America.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

LOGENEX Pharm GmbH is an independent German pharmaceutical company specializing in the development and distribution of high-quality generics and niche products. The product portfolio includes Anatrofer® 1000 mg (gastro-resistant tablets for metabolic acidosis treatment in chronic kidney disease patients), Bortezomib 3.5 mg (injection solution), Pemetrexed 500 mg (infusion solution), Testosteron 1000 mg/4 mg (injection solution), and Zoledronsäure 4 mg/5 ml (infusion solution concentrate). All products are manufactured in certified production facilities within the European Union following Good Manufacturing Practice (GMP) guidelines.

Product and service1 record
1Anatrofer 1000 mg (Sodium hydrogen carbonate)
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

PharmIdea SIA focuses on research and manufacturing of medications for hospitals, specializing in gynecology and oncology. They have core competencies in research, development and production of sterile formulations. LOGENEX partners with PharmIdea for product development.

2CareCept Medical
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

CareCept medical specializes in pharmaceutical distribution in Germany with particular focus on oncology. They serve as the sales and distribution partner for LOGENEX products in the German market.

logenex-pharm.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

CNX Therapeutics distributes a portfolio of specialty brands and hospital products in Europe and through partners in over 35 countries worldwide. They are a key distribution partner for LOGENEX's international expansion.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

German-headquartered generics and specialty pharmaceutical company with broad European distribution and a hospital/oncology portfolio — the closest direct comparable to LOGENEX in scale, geography, and therapeutic mix.

TypeBroad incumbent
Description

Well-established German generics brand under Teva with broad OTC/Rx portfolio, large-scale distribution and significant presence in the same hospital tender markets LOGENEX targets.

TypeDirect peer
Description

German specialty generics company focused on hospital injectables and oncology, with cross-border distribution — directly comparable therapeutic and channel mix to LOGENEX.

TypeEmerging player
Description

EU-based sterile formulation CDMO specializing in oncology and gynecology injectables; LOGENEX's co-development partner but also a peer in sterile injectable capabilities for hospital channels.

TypeDirect peer
Description

Specialty and hospital pharmaceutical distributor operating across Europe and 35+ countries — both a key channel partner and an operational peer given its overlapping oncology and hospital product portfolio.

TypeDirect peer
Description

Independent German pharmaceutical company with branded generics and specialty products, including nephrology adjacencies — comparable in operating model and German-market positioning.

TypeBroad incumbent
Description

Major German generics subsidiary of Sandoz with extensive hospital and CKD-relevant product lines; competes head-to-head with LOGENEX in the German generics and nephrology-adjacent space.

8CareCept Medical
TypeDirect peer
Description

German pharmaceutical distributor with an oncology focus; LOGENEX's domestic sales partner and a structural peer in niche hospital oncology distribution in Germany.

TypeDirect peer
Description

German specialty pharma focused on niche and rare-disease generics, including nephrology — comparable as a similarly sized, niche-focused German generics specialist.

TypeBroad incumbent
Description

Subsidiary of a major Indian generics group active in European hospital injectables, including oncology — competes on price and scale in the same tenders LOGENEX addresses.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Logenex Pharm Gmbh

Generic Pharmaceuticalslogenex-pharm.com

LOGENEX Pharm GmbH is an independent German pharmaceutical company based in Hamburg that develops and distributes EU-manufactured generic and niche pharmaceuticals, primarily for nephrology (CKD metabolic acidosis) and oncology, via a partner distribution network across Europe, North Africa, the Middle East, Southeast Asia, and Latin America.

What Logenex Pharm Gmbh does

LOGENEX Pharm GmbH is a privately held German pharmaceutical company headquartered at Martinistrasse 13, Hamburg, operating under the legal form of a Gesellschaft mit beschränkter Haftung (GmbH). The company specializes in the development and distribution of high-quality generic and niche pharmaceuticals targeted at specific therapeutic areas, with a current product portfolio of five core SKUs: Anatrofer® 1000 mg (sodium hydrogen carbonate gastro-resistant tablets for metabolic acidosis in chronic kidney disease), Bortezomib 3.5 mg injection, Pemetrexed 500 mg infusion, Testosteron 1000 mg/4 mg injection, and Zoledronsäure 4 mg/5 ml infusion concentrate. All products are manufactured, tested, and released in certified production facilities within the European Union in strict accordance with Good Manufacturing Practice (GMP) guidelines; the company itself holds a wholesale distribution authorization under § 52a (1) of the German Medicines Act (AMG), issued by the Hamburg authority responsible for medicinal products and consumer protection.

The company operates an asset-light, B2B go-to-market model. Products are registered and marketed through a network of distribution partners across Europe, North Africa, the Middle East, Southeast Asia, and Latin America. Three partners anchor the distribution architecture: CNX Therapeutics handles international specialty and hospital channels across 35+ countries, CareCept Medical serves as the sales and distribution partner in Germany with a focus on oncology, and PharmIdea SIA functions as a strategic co-development partner for sterile formulation manufacturing in gynecology and oncology. End customers are healthcare professionals, hospital systems, and patients requiring treatment in nephrology (specifically CKD-related metabolic acidosis) and oncology. Revenue is generated through product sales via this partner channel structure; the company lists "one-time license" revenue streams and pricing is not publicly disclosed. The organization is led by General Manager (Geschäftsführer) Frank Materne, with no disclosed external ownership, venture backing, or public listing.

The company's competitive positioning rests on EU GMP manufacturing provenance, a niche therapeutic focus in CKD metabolic acidosis and oncology, and supply reliability for healthcare system partners. The headquarters is registered with the District Court of Hamburg under HRB 110224.

Logenex Pharm Gmbh firmographics

Firmographics
Name
Logenex Pharm Gmbh
Legal name
LOGENEX Pharm GmbH
Website
https://logenex-pharm.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
LOGENEX Pharm GmbH is an independent German pharmaceutical company based in Hamburg that develops and distributes EU-manufactured generic and niche pharmaceuticals, primarily for nephrology (CKD metabolic acidosis) and oncology, via a partner distribution network across Europe, North Africa, the Middle East, Southeast Asia, and Latin America.
Ownership category
akta.pro rank

Logenex Pharm Gmbh industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIAJAA
Full-Line Pharmaceutical Wholesalers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Generic pharmaceuticals
  • Pharmaceutical wholesale distribution
  • Nephrology therapeutics
  • Oncology generics
  • Hospital specialty medicines

Where Logenex Pharm Gmbh is headquartered

Location

Headquarters

HQ city
Hamburg
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Logenex Pharm Gmbh business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Generic Pharmaceuticals: Development and distribution of high-quality generic pharmaceuticals and niche products for specific therapeutic areas including chronic kidney disease and oncology.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Logenex Pharm Gmbh product offering

Product offering

Core offering

LOGENEX Pharm GmbH is an independent German pharmaceutical company that develops and distributes high-quality generic and niche pharmaceutical products for specific therapeutic areas, primarily chronic kidney disease (metabolic acidosis) and oncology. Products are sourced exclusively from qualified manufacturers within the European Union and manufactured, tested, and released under strict Good Manufacturing Practice (GMP) guidelines. Marketing and distribution are executed through a network of wholesale and channel partners across Europe, North Africa, the Middle East, Southeast Asia, and Latin America.

Product overview

LOGENEX Pharm GmbH is an independent German pharmaceutical company specializing in the development and distribution of high-quality generics and niche products. The product portfolio includes Anatrofer® 1000 mg (gastro-resistant tablets for metabolic acidosis treatment in chronic kidney disease patients), Bortezomib 3.5 mg (injection solution), Pemetrexed 500 mg (infusion solution), Testosteron 1000 mg/4 mg (injection solution), and Zoledronsäure 4 mg/5 ml (infusion solution concentrate). All products are manufactured in certified production facilities within the European Union following Good Manufacturing Practice (GMP) guidelines.

Differentiator

Problem solved

Functional benefit

Products and services

  • Anatrofer 1000 mg (Sodium hydrogen carbonate)

Companies that use Logenex Pharm Gmbh

Customer profile

Segments2 records

Ideal customer profiles2 records

Logenex Pharm Gmbh technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Logenex Pharm Gmbh partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • PharmIdea SIAcoreStrategic or Co-development PartnerPharmIdea SIA focuses on research and manufacturing of medications for hospitals, specializing in gynecology and oncology. They have core competencies in research, development and production of sterile formulations. LOGENEX partners with PharmIdea for product development.
  • CareCept MedicalcoreChannel Partner/ Reseller/ DistributorCareCept medical specializes in pharmaceutical distribution in Germany with particular focus on oncology. They serve as the sales and distribution partner for LOGENEX products in the German market.
  • CNX TherapeuticscoreChannel Partner/ Reseller/ DistributorCNX Therapeutics distributes a portfolio of specialty brands and hospital products in Europe and through partners in over 35 countries worldwide. They are a key distribution partner for LOGENEX's international expansion.

Scale indicators1 record

Recent moves7 records

Expansion highlights4 records

Logenex Pharm Gmbh competitors and assessment

Company assessment

Direct peers

  • STADA Arzneimittel AG: German-headquartered generics and specialty pharmaceutical company with broad European distribution and a hospital/oncology portfolio — the closest direct comparable to LOGENEX in scale, geography, and therapeutic mix.
  • Tillomed Pharma GmbH: German specialty generics company focused on hospital injectables and oncology, with cross-border distribution — directly comparable therapeutic and channel mix to LOGENEX.
  • CNX Therapeutics: Specialty and hospital pharmaceutical distributor operating across Europe and 35+ countries — both a key channel partner and an operational peer given its overlapping oncology and hospital product portfolio.
  • Medice Arzneimittel Pütter GmbH: Independent German pharmaceutical company with branded generics and specialty products, including nephrology adjacencies — comparable in operating model and German-market positioning.
  • CareCept Medical: German pharmaceutical distributor with an oncology focus; LOGENEX's domestic sales partner and a structural peer in niche hospital oncology distribution in Germany.
  • HORMOSAN Pharma GmbH: German specialty pharma focused on niche and rare-disease generics, including nephrology — comparable as a similarly sized, niche-focused German generics specialist.

Broad incumbents

  • ratiopharm (Teva): Well-established German generics brand under Teva with broad OTC/Rx portfolio, large-scale distribution and significant presence in the same hospital tender markets LOGENEX targets.
  • Hexal AG (Sandoz): Major German generics subsidiary of Sandoz with extensive hospital and CKD-relevant product lines; competes head-to-head with LOGENEX in the German generics and nephrology-adjacent space.
  • Aurobindo Pharma Deutschland: Subsidiary of a major Indian generics group active in European hospital injectables, including oncology — competes on price and scale in the same tenders LOGENEX addresses.

Emerging players

  • PharmIdea SIA: EU-based sterile formulation CDMO specializing in oncology and gynecology injectables; LOGENEX's co-development partner but also a peer in sterile injectable capabilities for hospital channels.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Logenex Pharm Gmbh social profiles

Digital presence

Logenex Pharm Gmbh compliance and trust

Trust signal

Compliance1 record

Logenex Pharm Gmbh financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Logenex Pharm Gmbh leadership team

Management profile

Number of profiles

Profiles1 record

Logenex Pharm Gmbh funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Logenex Pharm Gmbh M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Logenex Pharm Gmbh

What does Logenex Pharm Gmbh do?

LOGENEX Pharm GmbH is an independent German pharmaceutical company that develops and distributes high-quality generic and niche pharmaceutical products for specific therapeutic areas, primarily chronic kidney disease (metabolic acidosis) and oncology. Products are sourced exclusively from qualified manufacturers within the European Union and manufactured, tested, and released under strict Good Manufacturing Practice (GMP) guidelines. Marketing and distribution are executed through a network of wholesale and channel partners across Europe, North Africa, the Middle East, Southeast Asia, and Latin America.

Is Logenex Pharm Gmbh a public or private company?

Logenex Pharm Gmbh is a private company. It is classified as unknown and is currently operating.

When was Logenex Pharm Gmbh founded?

Logenex Pharm Gmbh was founded in 2009. It employs 1 to 10 people.

Where is Logenex Pharm Gmbh based?

Logenex Pharm Gmbh is headquartered in Hamburg, Germany, in the Europe region.

How does Logenex Pharm Gmbh make money?

One revenue line is on record: generic Pharmaceuticals.

Who are Logenex Pharm Gmbh's main competitors?

Direct peers on record are STADA Arzneimittel AG, Tillomed Pharma GmbH, CNX Therapeutics, Medice Arzneimittel Pütter GmbH, CareCept Medical and HORMOSAN Pharma GmbH. Broad incumbents are ratiopharm (Teva), Hexal AG (Sandoz) and Aurobindo Pharma Deutschland. PharmIdea SIA is listed as an emerging player.

Does Logenex Pharm Gmbh have an API?

No public API is recorded for Logenex Pharm Gmbh.

What industry is Logenex Pharm Gmbh in?

Logenex Pharm Gmbh's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAIAJAA, Full-Line Pharmaceutical Wholesalers. Its NAICS code is 325412 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales